Stock KTTA PASITHEA THERAPEUTICS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Pasithea Therapeutics Corp.

Equities

KTTA

US70261F2020

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 02:00:00 01/05/2024 am IST 		5-day change 1st Jan Change
6.92 USD -.--% Intraday chart for Pasithea Therapeutics Corp. -0.43% -6.49%
24/04 Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers CI
29/03 Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 38.74 18.77 7.71
Enterprise Value (EV) 1 -14.22 -13.45 -8.54
P/E ratio -8.47 x -1.16 x -0.57 x
Yield - - -
Capitalization / Revenue 2,57,21,94,728 x 3,85,74,720 x -
EV / Revenue -94,43,83,814 x -2,76,45,426 x -
EV / EBITDA 31,56,725 x 9,09,847 x 5,57,033 x
EV / FCF 94,50,797 x 13,50,459 x 11,66,983 x
FCF Yield 0% 0% 0%
Price to Book 0.79 x 0.39 x 0.33 x
Nbr of stocks (in thousands) 1,094 1,462 1,042
Reference price 2 35.40 12.83 7.400
Announcement Date 30/03/22 30/03/23 29/03/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales - 0.0151 0.4866 -
EBITDA - -4.506 -14.78 -15.33
EBIT 1 -0.041 -4.507 -14.82 -15.98
Operating Margin - -29,925.73% -3,045.12% -
Earnings before Tax (EBT) 1 -0.041 -2.174 -13.94 -15.51
Net income 1 -0.041 -2.174 -13.94 -15.96
Net margin - -14,430.49% -2,864.29% -
EPS - -4.178 -11.04 -13.01
Free Cash Flow - -1.505 -9.96 -7.318
FCF margin - -9,992.64% -2,047.11% -
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 13/04/21 30/03/22 30/03/23 29/03/24
1USD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2
Net sales 1 - 0.0151 0.0137 0.0136 0.2186 0.2407 - -
EBITDA - -1.96 -2.4 -2.51 - - - -
EBIT - -1.956 - -3.08 - - - -
Operating Margin - -12,989.77% - -22,681.08% - - - -
Earnings before Tax (EBT) - - - - - - - -
Net income -1.526 - - - - - - -
Net margin - - - - - - - -
EPS -3.400 - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 18/11/21 30/03/22 16/05/22 15/08/22 14/11/22 30/03/23 12/05/23 11/08/23
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 - - - -
Net Cash position 1 0.24 53 32.2 16.2
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - -1.51 -9.96 -7.32
ROE (net income / shareholders' equity) - -8.41% -29.7% -47.1%
ROA (Net income/ Total Assets) - -10.5% -18.8% -28%
Assets 1 - 20.67 74.12 56.97
Book Value Per Share 2 0.6500 44.70 32.60 22.50
Cash Flow per Share 2 0.6500 46.00 25.50 15.70
Capex - 0.02 0.37 0.03
Capex / Sales - 142.76% 77.05% -
Announcement Date 13/04/21 30/03/22 30/03/23 29/03/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
PASITHEA THERAPEUTICS CORP. Stock Pasithea Therapeutics Corp.
-6.49% 7.21M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.53% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+6.68% 97.47B
ARGENX SE Stock argenx SE
+5.71% 22.25B
BIONTECH SE Stock BioNTech SE
-12.73% 21.68B
GENMAB A/S Stock Genmab A/S
-9.70% 18.2B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.02B
BEIGENE, LTD. Stock BeiGene, Ltd.
-9.74% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.50% 14.39B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.08% 12.37B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. KTTA Stock
  4. Financials Pasithea Therapeutics Corp.